Medx Holdings Files for Federal DEA Cannabis Registration

Medx Holdings Inc. has submitted an application for Drug Enforcement Administration registration through its Lazydaze ABQ LLC subsidiary, positioning itself among a small cohort of publicly traded companies seeking federal approval to handle medical cannabis.

The filing represents a strategic bet on the federal government's evolving stance toward medical marijuana, particularly as DEA registration becomes increasingly critical for companies operating in states with medical programs. Medx operates retail locations across multiple markets, though the company has not disclosed which specific facilities would be covered under the federal registration.

"This submission marks a pivotal step in our mission to normalize and expand access to federally compliant medical cannabis," the company stated in its announcement.

The Federal Registration Landscape

DEA registration for cannabis handlers remains rare, with only a handful of entities authorized to grow, distribute, or research marijuana under federal law. The University of Mississippi held a monopoly on federally legal cannabis cultivation for decades until the DEA expanded the program in recent years.

Publicly traded companies pursuing this path face unique compliance challenges. They must navigate both federal requirements and state-level regulations while managing investor expectations in an industry where federal illegality has historically limited institutional investment.

Medx's decision to file through Lazydaze ABQ—its Albuquerque-based entity—suggests the company may be leveraging New Mexico's medical cannabis framework as its entry point. New Mexico has operated a medical marijuana program since 2007 and added adult-use sales in 2022.

What DEA Approval Means

If granted, federal registration would allow Medx to operate under DEA oversight while handling Schedule I controlled substances. This status could provide several advantages:

• Enhanced legitimacy with banking partners and institutional investors
• Potential access to interstate commerce pathways if federal policy shifts
• Ability to participate in federally sanctioned research programs
• Possible tax advantages compared to operators subject to 280E restrictions

But the approval process is neither quick nor guaranteed. The DEA conducts extensive background checks, facility inspections, and security assessments before granting registration. Previous applicants have waited months or years for determinations.

Industry Context

The move comes as the cannabis industry watches closely for potential federal rescheduling. The DEA has been reviewing marijuana's Schedule I classification following a recommendation from the Department of Health and Human Services to move it to Schedule III.

Rescheduling wouldn't legalize cannabis outright, but it would significantly alter the regulatory landscape for medical marijuana companies. Schedule III substances can be prescribed by physicians and face less restrictive handling requirements than Schedule I drugs.

Medx's proactive filing suggests the company is positioning itself ahead of potential regulatory changes rather than waiting for the federal landscape to settle. Other multi-state operators have taken different approaches—some expanding state-level operations while avoiding federal entanglements, others pursuing research partnerships with federally approved entities.

What's Next

The company has not disclosed a timeline for when it expects the DEA to rule on its application. Federal registration applications typically undergo review periods of six months to over a year, depending on complexity and the agency's current workload.

Medx will need to maintain compliance with both state regulations and federal requirements throughout the review process. Any operational changes at Lazydaze ABQ during this period could impact the application's status.

Investors and industry observers will be watching whether other public companies follow Medx's lead in pursuing federal registration, particularly if the DEA signals more openness to approving such applications.

---

This article is based on original reporting by www.globenewswire.com.